AstraZeneca's Real-Life Study on Benralizumab: Market Implications and Progress
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: AstraZeneca is conducting a non-interventional, prospective study titled A Non-interventional, Prospective Study With Benralizumab to Investigate Clinical Outcome Based on Standard of Care Medication in Real-life. The study aims to assess asthma control, health-related quality of life, lung function, and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in Germany. This research is significant as it evaluates real-life outcomes of benralizumab, providing insights into its effectiveness in routine clinical practice.
Intervention/Treatment: The study focuses on benralizumab, a monoclonal antibody used to treat severe eosinophilic asthma. It aims to improve asthma control and quality of life by targeting and reducing eosinophils, a type of white blood cell involved in asthma inflammation.
Study Design: This is an observational cohort study with a prospective time perspective. It involves a single-arm, multicenter approach where patients' asthma control and quality of life are monitored using various questionnaires and diaries over a 52-week period.
Study Timeline: The study began on July 25, 2024, with its primary completion and estimated completion dates yet to be announced. The most recent update was submitted on July 15, 2025. These dates are crucial for tracking the study's progress and anticipating future findings.
Market Implications: The ongoing study could influence AstraZeneca's stock performance by showcasing benralizumab's real-world effectiveness, potentially boosting investor confidence. As the asthma treatment market is competitive, positive results may enhance AstraZeneca's position against competitors, impacting market dynamics and investor sentiment.
The study is currently recruiting, with further details available on the ClinicalTrials portal.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
VNBTC Gains UK FCA Certification, Enhancing Trust in Its Cloud Mining Platform for Simple and Secure Bitcoin Earnings
LONDON, July 21, 2025 (GLOBE NEWSWIRE) -- Institutional investment and global interest have driven the Bitcoin price past $120,000. Simultaneously, cloud mining is evolving into a powerful, accessible way to earn cryptocurrency. VNBTC, a cloud mining platform headquartered in the UK, is proud to announce that it has officially received regulatory certification from the UK's Financial Conduct Authority (FCA). This significant milestone marks VNBTC as one of the few legally recognized cloud mining platforms in the global crypto space — reinforcing its commitment to compliance, investor protection, and long-term sustainability. With its new FCA status, VNBTC now offers crypto investors worldwide a higher level of trust and transparency. The certification enables VNBTC to operate under strict regulatory guidelines, adding a legal layer of security to its AI-optimized cloud mining services. Users can now confidently access Bitcoin, Dogecoin, and Litecoin mining contracts knowing they are engaging with a fully licensed and regulated service provider. In 2025, VNBTC has emerged as a standout platform, offering tiered cloud-mining contracts that deliver impressive earning potential, even for beginners. The platform's signature feature? Clearly defined daily ROI and transparent contract mechanics, making it easy to estimate your returns before you invest. Due to these plan structures, the highest-paying Bitcoin contract offers $17,500 ROI. VNBTC credits earnings automatically every 24 hours to your dashboard, so users see their profits grow in real time and can withdraw or reinvest at any time. With millions of investors already using the platform's AI-optimized contracts, many are seeing daily income ranging from modest starter-plan payouts to five-figure profit cycles. VNBTC is making cryptocurrency mining easier, offering multiple ways to earn passively without needing to afford expensive mining rigs. With added benefits like the affiliate program offering 3% and 1.8% referral commission. Now might be the best time to join the future of mining that is globally trusted by millions. Media Contact: James Carter Marketing Specialist
Globe and Mail
2 hours ago
- Globe and Mail
Will Broad Cloud Access Boost Momentum for Oracle's Hardware Business?
Oracle ORCL is leveraging its partnerships with top cloud providers to accelerate the momentum of its hardware business. By integrating Exadata X11M systems and Autonomous Database infrastructure into data centers operated by Amazon Web Services (AWS), Microsoft Azure and Google Cloud, the company's multicloud strategy enables enterprises to access its high-performance database services within their preferred ecosystems. This approach reduces dependency on Oracle's own cloud while significantly expanding its hardware reach across global markets. Recent initiatives highlight this expansion. Oracle Database@Google Cloud launched in Japan, offering Exadata-powered services through Google's data centers, while Oracle Database@AWS allows seamless database workload migration to AWS' scalable infrastructure. These moves are expected to boost the hardware segment's top-line growth through the sale and installation of Exadata systems, storage servers and database machines, along with hardware costs capitalized and recovered over time via cloud subscriptions. To further meet rising demand, Oracle is aligning its hardware with AI growth by integrating Nvidia's latest GPUs and committing more than $40 billion to procure 400,000 Nvidia GB200 chips for its Stargate AI data center in Texas. Planned investments of $2 billion in Germany and $1 billion in the Netherlands underscore its commitment to scaling high-performance infrastructure through advanced hardware solutions. Oracle's hardware revenues are projected to reach $3 billion in fiscal 2026, following a 6.82% year-over-year increase in fourth-quarter fiscal 2025, highlighting the strength of its partnership-led growth model. Oracle Faces Tough Competition in Hardware Space Oracle faces stiff competition in advanced Hardware solutions from players like Hewlett-Packard HPE and Dell Technologies DELL. Hewlett-Packard offers powerful hardware solutions that support advanced computing, storage and networking facilities along with AI workloads. Hewlett-Packard's ProLiant Gen11 servers, featuring AMD EPYC Genoa chips and liquid-cooled GB200 NVL72 racks, target demanding AI workloads. With innovations like the XD690 housing eight NVIDIA GPUs, Hewlett-Packard delivers hybrid-cloud, energy-efficient hardware that rivals Oracle's Exadata in modern enterprise environments. Dell Technologies offers PowerEdge servers and PowerStore/PowerMax storage as flexible alternatives to Oracle's Exadata. While Exadata can deliver up to 36× higher I/O performance, Dell Technologies drives appeal through its VxRail hyper-converged systems, offering flexibility and cost savings. A major power company switched from Exadata to Dell Technologies' VxRail, reducing Oracle licensing exposure and saving over $5 million in total project costs. ORCL's Price Performance, Valuation & Estimates Shares of Oracle have appreciated 47.3% year to date, underperforming both the Zacks Computer and Technology sector's return of 9.5% and the Zacks Computer - Software industry's appreciation of 19.2%. ORCL's YTD Price Performance From a valuation standpoint, ORCL appears overvalued, trading at a trailing 12-month EV/EBITDA multiple of 30.15x, significantly higher than the Zacks industry's average of 20.55x. Oracle carries a Value Score of F. ORCL's Valuation The Zacks Consensus Estimate for ORCL's fiscal 2026 revenues is pegged at $66.57 billion, indicating 15.97% year-over-year growth. The consensus mark for ORCL's 2026 earnings is pegged at $6.73 per share, increased by a couple of cents over the past 30 days. The earnings figure suggests 11.61% growth over the figure reported in fiscal 2025. ORCL currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. One Big Gain, Every Trading Day To help you take full advantage of this market, you're invited to access every stock recommendation in all our private portfolios - for just $1. Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That's about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%. Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dell Technologies Inc. (DELL): Free Stock Analysis Report Oracle Corporation (ORCL): Free Stock Analysis Report Hewlett Packard Enterprise Company (HPE): Free Stock Analysis Report
Globe and Mail
3 hours ago
- Globe and Mail
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Key Points Pfizer and Novo Nordisk have underperformed the market over the past year. But both should remain major players in important areas within the pharma industry. Investors could see the two drugmakers' shares beat the market over the next decade. 10 stocks we like better than Pfizer › Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further. Though these companies have encountered challenges, there are good reasons to be bullish on their long-term prospects. Pfizer could become an even bigger player in the oncology market (the largest therapeutic area in the industry by sales) over the next decade, while Novo Nordisk will be a major player in diabetes and the fast-growing weight management space. Both could produce excellent results along the way. Here's the rundown. 1. Pfizer Pfizer's financial results haven't been great in recent years. To make matters worse, the company will face important patent cliffs by the end of the decade. One of them will be for Eliquis, an anticoagulant that is still one of its best-selling medicines. However, Pfizer has prepared for that eventuality. The company made several acquisitions and licensing deals that significantly boosted its pipeline, especially in oncology. Pfizer spent $43 billion to acquire Seagen, a smaller cancer specialist whose lineup and pipeline were impressive for a company of its size. With the financial and strategic backing of the larger company, it should yield even more key approvals in the field in the coming years. Pfizer also recently made an up-front payment of $1.25 billion to China-based 3SBio for the rights to SSGJ-707, an investigational bispecific antibody, a portion of the oncology market that's gaining traction these days. 3SBio will be eligible for commercial and regulatory milestone payments of up to $4.8 billion, not including royalties. These moves should eventually pay off for Pfizer and strengthen its position in oncology. The drugmaker plans to have eight blockbuster cancer medicines on the market by 2030, up from its current five, while doubling its reach from the current 1 million patients it serves. Of course, Pfizer isn't just a cancer play. The company's extensive pipeline should enable it to launch products in other areas and ultimately get back on track. While its shares have been lagging the market significantly, that could change in the next decade as financial results rebound thanks to its innovative efforts. Pfizer's shares look especially attractive when considering its valuation. Its forward price-to-earnings (P/E) ratio is 8.7, much lower than the healthcare sector 's 15.8. From their current levels, Pfizer's shares could go on to generate excellent returns through 2035. 2. Novo Nordisk Novo Nordisk pioneered the market for weight management medicines. However, Eli Lilly seems to have taken the lead in that field, at least for now. Novo Nordisk has faced some clinical setbacks, leading to a poor performance over the trailing-12-month period. Can the company rebound and perform well in the next decade? In my view, it can, and the market may be significantly undervaluing its potential. Its sales of Wegovy, one of the top-selling anti-obesity medications, continue to grow rapidly. Novo Nordisk recently requested approval from the U.S. Food and Drug Administration for oral semaglutide (the active ingredient in Wegovy). That's good for patients who want a non-injected option, and helps counter Lilly's up-and-coming oral GLP-1 medicine, orforglipron. Elsewhere, Novo Nordisk recently started phase 3 studies for amycretin, a next-gen weight loss candidate. Amycretin is being investigated in both oral and subcutaneous formulations, and both are currently in late-stage clinical trials. The company also enhanced its pipeline through licensing deals, including one with United Biotechnology, a subsidiary of the China-based company United Laboratories International Holdings, for UBT251. This potential anti-obesity medicine mimics the actions of three gut hormones: GLP-1, GIP, and glucagon. The transaction cost Novo Nordisk an up-front payment of $200 million and up to $1.8 billion in milestone payments. Thanks to all these developments, Novo Nordisk should remain a leader in weight management in the next decade. Even though competition is mounting, no drugmaker not named Eli Lilly has a lineup or a pipeline as deep as Novo Nordisk's. Furthermore, the Denmark-based pharmaceutical leader will also continue to dominate the diabetes market, as it has done for decades. Novo Nordisk generates consistent revenue and earnings that typically grow faster than those of similarly-sized peers. Yet the stock's forward P/E is 16.7, which is slightly above the industry average. In my view, that's a bargain for a company that generates better-than-average results and has a deep pipeline in a fast-growing area -- not to mention two of the world's top 20 best-selling drugs, in Wegovy and Ozempic. For investors willing to stay the course, Novo Nordisk's future still looks incredibly bright. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
